Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Assets Average: 2009-2025

Historic Assets Average for Gyre Therapeutics (GYRE) over the last 17 years, with Sep 2025 value amounting to $156.0 million.

  • Gyre Therapeutics' Assets Average rose 26.75% to $156.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $156.0 million, marking a year-over-year increase of 26.75%. This contributed to the annual value of $121.0 million for FY2024, which is 20.20% up from last year.
  • Gyre Therapeutics' Assets Average amounted to $156.0 million in Q3 2025, which was up 10.48% from $141.2 million recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Assets Average registered a high of $156.0 million during Q3 2025, and its lowest value of $11.2 million during Q3 2023.
  • Its 3-year average for Assets Average is $96.0 million, with a median of $121.5 million in 2024.
  • Its Assets Average has fluctuated over the past 5 years, first slumped by 80.45% in 2023, then spiked by 1,001.03% in 2024.
  • Gyre Therapeutics' Assets Average (Quarterly) stood at $67.1 million in 2021, then fell by 13.73% to $57.9 million in 2022, then grew by 9.27% to $63.3 million in 2023, then surged by 98.13% to $125.3 million in 2024, then rose by 26.75% to $156.0 million in 2025.
  • Its last three reported values are $156.0 million in Q3 2025, $141.2 million for Q2 2025, and $127.6 million during Q1 2025.